CorAssist Cardiovascular CORolla^® Device for Treatment of Heart Failure with Preserved Ejection Fraction (HFpEF)

Introduction: CorAssist is developing innovative device based technologies for treatment of Heart Failure with Preserved Ejection Fraction (HFpEF). The underlying mechanism for HFpEF is diastolic dysfunction, a clinical syndrome that impairs the ability of the left ventricle (LV) to fill with blood, due to impaired LV relaxation and /or stiffened myocardium. HFpEF accounts for ~50% of all heart failure cases. At present, no proven pharmaceutical or device based therapeutic solutions exist for HFpEF patients.

Technology: CorAssist has developed “spring like” elastic devices which harness the elastic energy produced by the LV during systole (contraction) and release the energy to the LV during diastole (relaxation), thus transferring energy from systole to diastole to augment LV diastolic dynamics. The primary product CORolla ® (Intra-Left-Ventricular device), is an implantable elastic spring-like device. The device is implanted in the left ventricle through a Trans-Apical Approach (TAA).

Clinical Status: Following extensive pre-clinical studies, lately a First-in-Men stand-alone implantation was conducted at Rambam Healthcare Campus.